الفهرس 
HCV treatment in the era of DAAsOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Summary
Egypt is known to be among the countries with highest HCV
prevalence, with HCV genotype-4 being the predominant
genotype in Egypt. The availability of DAAs with excellent
efficacy and good tolerability profiles offer a unique opportunity
to achieve HCV elimination worldwide. DAA combinations can
now cure HCV in more than 95% of patients with HCV infection
after 12 weeks of treatment. However, viral clearance with DAAs
has led to a global worsening of lipid profile.
The purpose of this work was to study the changes in serum
lipid profile with INF-free treatment regimens in chronic HCV
infection and its association with treatment outcome, and its
possible use as a predictor of response to therapy.
This prospective observational cohort study was carried out in
the Viral Hepatitis Treatment Unit at Tanta University Teaching
Hospital. The study included 301 patients with chronic HCV
infection, who were treated according to NCCVH treatment
protocol. Patients who received antiviral therapy and completed
their course of HCV therapy and follow up were included and
were divided into two groups according to treatment response.
There were 264 patients (88%) who achieved an SVR. Only 4%